Previous 10 | Next 10 |
Are These The Best Biotech Stocks To Watch This Week? Biotech stocks have been riding a wave of success in the stock market this year. Investors looking for high growth investments have been paying attention to top biotech stocks in the last few months. The biotech indus...
Surprisingly enough, one of the best performing coronavirus vaccine stocks of the year is Arcturus Therapeutics (NASDAQ: ARCT) . If you had invested $10,000 in the San-Diego based biotech last year, that principal would have grown to a stunning $101,000 as of Dec. 4. That ...
This might be the year for mRNA drugs. The most prominent name in this space, Moderna , is up a fantastic 700% in 2020. And returns for BioNTech haven't been too shabby with its stock quadrupling in a year. While those investors certainly aren't complaining, the biggest mRNA winner ...
Gainers: [[TPGY]] +99%. [[GIK]] +17.4%. [[AHT]] +15.8%. [[FEIM]] +13.9%. [[RMG]] +9.5%.Losers: [[NBRV]] -14.7%. [[OPCH]] -10.1%. [[PHX]] -8.9%. [[CASA]] -6.3%. [[ARCT]] -5.2%. For further details see: AHT, ARCT, NBRV and RMG among after-hours movers
Sing along to the tune of "Rudolph, the Red-Nosed Reindeer": "You know Pfizer and BioNTech , Moderna , AstraZeneca . But do you recall...the most promising dark-horse COVID vaccine maker of all?" Many investors might not know which company this admittedly clunky ...
On Tuesday, shares of up-and-coming biotechs Marinus Pharmaceuticals (NASDAQ: MRNS) , iBio (NYSEMKT: IBIO) , and Arcturus Therapeutics Holdings (NASDAQ: ARCT) fell by 12%, 13%, and 19%, respectively. One common catalyst seems to be the secondary-share issues anno...
Gainers: Curis (CRIS) +335%.Lexicon Pharmaceuticals (LXRX) +97%.Mammoth Energy Services (TUSK) +61%.NeuroMetrix (NURO) +49%.Stitch Fix (SFIX) +45%.IGM Biosciences (IGMS) +38%.Blonder Tongue Laboratories (BDR) +26%.Infinity Pharmaceuticals (INFI) +25%.KLX Energy Services (KLXE) +24%....
Arcturus Therapeutics (ARCT) has priced its public offering of ~1.37M common shares at $110.00/share, for expected gross proceeds of ~$150M.Underwriters' over-allotment is an additional ~205K shares. Net proceeds will be used to conduct clinical trials and commence manufacturing of LUNAR-COV1...
Arcturus Therapeutics Holdings Inc. (the “Company”, NASDAQ: ARCT), a leading clinical-stage messenger RNA medicines company focused on the development of infectious disease vaccines and significant opportunities within liver and respiratory rare diseases, today announced t...
Gainers: [[SFIX]] +33.8%. [[PLG]] +16.9%. [[SMAR]] +14.6%. [[HOLI]] +12.7%. [[KODK]] +8.6%.Losers: [[FRAN]] -19%. [[OBLN]] -11.3%. [[ARCT]] -6%. [[STRO]] -4%. [[EVK]] -3%. For further details see: SFIX, KODK, ARCT and FRAN among after-hours movers
News, Short Squeeze, Breakout and More Instantly...
Arcturus Therapeutics Ltd. Company Name:
ARCT Stock Symbol:
NASDAQ Market:
Arcturus Therapeutics Ltd. Website:
Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a global messenger RNA medicines company focused on the development of infectious disease vaccines and medicines to treat unmet medical needs within liver and respiratory rare diseases, toda...
2024-07-02 10:15:03 ET Piper Sandler analyst issues OVERWEIGHT recommendation for ARCT on July 2, 2024 08:19AM ET. The previous analyst recommendation was Overweight. ARCT was trading at $23.66 at issue of the analyst recommendation. The overall analyst consensus : BUY. ...
ARCT-810 Phase 2 study completed enrollment at 0.3 mg/kg dose level in Europe with data expected later this year ARCT-810 to expand Phase 2 clinical program in the U.S. to enroll patients with more severe disease ARCT-032 IND for Phase 2 multiple ascending dose study to be submitt...